Ironwood Pharmaceuticals Inc (IRWD)

IRWD (NASDAQ:Drugs) EQUITY
$16.87
neg -0.25
-1.46%
Today's Range: 16.39 - 17.49 | IRWD Avg Daily Volume: 1,223,700
Last Update: 02/22/17 - 4:00 PM EST
Volume: 1,391,390
YTD Performance: 11.97%
Open: $17.12
Previous Close: $17.12
52 Week Range: $7.35 - $14.35
Oustanding Shares: 146,223,549
Market Cap: 2,506,271,630
6-Month Chart
TheStreet Ratings Grade for IRWD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 4 4
Moderate Buy 0 0 0 0
Hold 4 4 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.00 2.00 2.00 2.00
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -32.96
Price Earnings Comparisons:
IRWD Sector Avg. S&P 500
-32.96 0.00 30.60
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
4.33% 88.96% 14.06%
GROWTH 12 Mo 3 Yr CAGR
Revenue 95.70 0.00 0.00
Net Income 0.00 1.00 0.00
EPS 0.00 0.50 0.00
Earnings for IRWD:
EBITDA -0.09B
Revenue 0.15B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $-0.11 $-0.04 $-0.33 $0.32
Number of Analysts 2 2 5 4
High Estimate $-0.10 $-0.03 $-0.07 $0.69
Low Estimate $-0.12 $-0.04 $-0.67 $-0.22
Prior Year $-0.08 $-0.16 $-0.55 $-0.33
Growth Rate (Year over Year) -37.50% 78.13% 39.27% 195.81%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA
By

Doug Kass

 | Dec 23, 2016 | 8:13 AM EST
Twelve-month upside $260 (+33%) Twelve-month downside $175 (-10%) AGN has a significant pipeline and a potentially important near-term catalyst:  The company and its partner, Ironwood Pharmaceuticals (IRWD) , have just announced good results from a Phase 2b trial that investigated delayed-release versions of Linzess. Well-tolerated with no adverse events, this holds large potential. CR1 (ileum), in particular, could significantly improve on the strengths of Linzess. More than one third of the CR1 patients have reported pai
RMPIA
By

Bret Jensen

 | Aug 22, 2016 | 7:54 AM EDT
Good morning, Bret Jensen here! It's good to be standing in for Doug Kass again on the daily diary as we begin a new trading week.
RMPIA
By

Bret Jensen

 | Jul 22, 2016 | 11:00 AM EDT
I expect Allergan or another player to bid for SGYP soon.

bullishIronwood upgraded at Cantor

Feb 6, 2015 | 7:43 AM EST

IRWD was upgraded form Sell to Hold, Cantor Fitzgerald said. Company lacks negative near-term catalysts. $13.50 price target. 

By

Bret Jensen

 | Dec 12, 2014 | 10:00 AM EST

Synergy Pharmaceuticals is developing drugs to treat gastrointestinal disorders and diseases. The

bearishIronwood downgraded at Cantor

Nov 6, 2014 | 6:54 AM EST

IRWD was downgraded from Hold to Sell, Cantor Fitzgerald said. $10 price target. Valuation call, as the company will likely spend more on R&D in the new year. 

bullishIronwood upgraded at Cantor

Jul 24, 2013 | 7:51 AM EDT

IRWD was upgraded to Hold, Cantor Fitzgerald said. $10 price target. Linzess can continue to grow and the company is keeping a tight lid on costs. 

bullishIronwood upgraded at Wedbush

May 30, 2013 | 8:09 AM EDT

IRWD was upgraded from Underperform to Neutral, Wedbush said. $12 price target. Linzess prescriptions are growing.

RMPIA
By

Gary Dvorchak

 | Apr 26, 2013 | 11:00 AM EDT

The negative surprises indicate hidden weakness in a business, and the stocks are to be avoided.

bearishIronwood Pharmaceutical downgraded at Wedbush

Apr 24, 2013 | 8:17 AM EDT

Shares of IRWD were downgraded to Underperform  from Neutral, said Wedbush. Cash burn is occurring much faster than expected given high R&D expenses. Price target is $12.

Here is a well defined zone to look for buy triggers against...defining the risk below it!...
this is the FOURTH big winner we have booked on Apple since December. SOLD AAPL APR 1...
Garmin is the top gainer in the S&P 500 today following this morning's...
Shares of Exxon Mobil  (XOM) have been declining steadily this year, and moved back d...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.